Balavanthapu Rajitha, Sastry Vedula Girija
Department of Chemistry, Andhra University, Vishakapatnam, Andra Pradesh, India.
Anticancer Agents Med Chem. 2025;25(11):765-773. doi: 10.2174/0118715206315373241014101856.
Cancer presents a significant global health challenge, necessitating effective treatment strategies. While chemotherapy is widely employed, its non-specific nature can induce adverse effects on normal cells, prompting the exploration of targeted therapies. The 1,2,4-triazole scaffold has emerged as a promising element in anticancer drug development due to its structural diversity and potential to target cancer cells.
This study aims to synthesize and evaluate novel derivatives derived from the 1,2,4-triazole scaffold for their potential as anticancer agents. Molecular docking techniques are employed to investigate the interactions between the designed derivatives and specific cancer-related targets, providing insights into potential underlying mechanisms.
The synthesis involves a three-step process to produce 5-oxo-1,2,4-triazole-3-carboxamide derivatives. Various analytical techniques, including NMR and HRMS, validate the successful synthesis. Molecular docking studies utilize X-ray crystal structures of EGFR and CDK-4 obtained from the Protein Data Bank, employing the Schrödinger suite for ligand preparation and Glide's extra-precision docking modes for scoring.
The synthesis yields compounds with moderate to good yields, supported by detailed characterization. Molecular docking scores for the derivatives against EGFR and CDK-4 revealed diverse affinities influenced by distinct substituents. Compounds with hydroxyl, and halogen, substitutions exhibited notable binding affinities, while alkyl and amino substitutions showed varying effects. The 1,2,4-triazole derivatives demonstrated potential for targeted cancer therapy.
The study highlights the successful synthesis of 5-oxo-1,2,4-triazole-3-carboxamides and their diverse interactions with cancer-related targets. The findings emphasized the potential of these derivatives as candidates for further development as anticancer agents, offering insights into structure-activity relationships. The 1,2,4-triazole scaffold stands out as a promising platform for advancing cancer treatment with enhanced precision and efficacy.
癌症是一项重大的全球健康挑战,需要有效的治疗策略。虽然化疗被广泛应用,但其非特异性本质会对正常细胞产生不良反应,这促使人们探索靶向治疗。1,2,4-三唑骨架因其结构多样性和靶向癌细胞的潜力,已成为抗癌药物开发中一个有前景的元素。
本研究旨在合成并评估源自1,2,4-三唑骨架的新型衍生物作为抗癌剂的潜力。采用分子对接技术研究设计的衍生物与特定癌症相关靶点之间的相互作用,以深入了解潜在的作用机制。
合成过程包括三步,用于制备5-氧代-1,2,4-三唑-3-甲酰胺衍生物。包括核磁共振(NMR)和高分辨质谱(HRMS)在内的各种分析技术验证了合成的成功。分子对接研究利用从蛋白质数据库获得的表皮生长因子受体(EGFR)和细胞周期蛋白依赖性激酶4(CDK-4)的X射线晶体结构,使用薛定谔软件包进行配体制备,并采用Glide的超精确对接模式进行评分。
合成得到了产率适中至良好的化合物,并通过详细的表征得到证实。衍生物对EGFR和CDK-4的分子对接评分显示,不同的取代基会影响其亲和力。具有羟基和卤素取代的化合物表现出显著的结合亲和力,而烷基和氨基取代则表现出不同的效果。1,2,4-三唑衍生物显示出靶向癌症治疗的潜力。
该研究突出了5-氧代-1,2,4-三唑-3-甲酰胺的成功合成及其与癌症相关靶点的多种相互作用。这些发现强调了这些衍生物作为抗癌剂进一步开发候选物的潜力,为构效关系提供了见解。1,2,4-三唑骨架是一个有前景的平台,有望提高癌症治疗的精度和疗效。